Inhibitors
An inhibitor contains naphthyridine dimer, a naphthyridine-azaquinolone hybrid, a trinaphthyridine-azaquinolone hybrid, or a trinaphthyridine-azaquinolone hybrid derivative. In order to inhibit binding of 100 nM of RRE to 100 nM of Rev protein, for example, an inhibitor containing naphthyridine dime...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | GOTO YUKI KOBORI AKIO NAKATANI KAZUHIKO HAGIWARA SHINYA HORIE SOUTA SAITO ISAO |
| description | An inhibitor contains naphthyridine dimer, a naphthyridine-azaquinolone hybrid, a trinaphthyridine-azaquinolone hybrid, or a trinaphthyridine-azaquinolone hybrid derivative. In order to inhibit binding of 100 nM of RRE to 100 nM of Rev protein, for example, an inhibitor containing naphthyridine dimer is used at a molarity of 1.2 muM to 12 muM, an inhibitor containing the naphthyridine-azaquinolone hybrid is used at a molarity of 2 muM to 20 muM, or an inhibitor containing the trinaphthyridine-azaquinolone hybrid derivative is used at a molarity of 200 nM to 2 muM. This makes it possible to effectively inhibit binding of RRE to Rev protein. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN100453547CC</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN100453547CC</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN100453547CC3</originalsourceid><addsrcrecordid>eNrjZODyzMvITMosyS8q5mFgTUvMKU7lhdLcDEpuriHOHrqpBfnxqcUFicmpeakl8c5-hgYGJqbGpibmzs7GRCkCAAPvHZI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Inhibitors</title><source>esp@cenet</source><creator>GOTO YUKI ; KOBORI AKIO ; NAKATANI KAZUHIKO ; HAGIWARA SHINYA ; HORIE SOUTA ; SAITO ISAO</creator><creatorcontrib>GOTO YUKI ; KOBORI AKIO ; NAKATANI KAZUHIKO ; HAGIWARA SHINYA ; HORIE SOUTA ; SAITO ISAO</creatorcontrib><description>An inhibitor contains naphthyridine dimer, a naphthyridine-azaquinolone hybrid, a trinaphthyridine-azaquinolone hybrid, or a trinaphthyridine-azaquinolone hybrid derivative. In order to inhibit binding of 100 nM of RRE to 100 nM of Rev protein, for example, an inhibitor containing naphthyridine dimer is used at a molarity of 1.2 muM to 12 muM, an inhibitor containing the naphthyridine-azaquinolone hybrid is used at a molarity of 2 muM to 20 muM, or an inhibitor containing the trinaphthyridine-azaquinolone hybrid derivative is used at a molarity of 200 nM to 2 muM. This makes it possible to effectively inhibit binding of RRE to Rev protein.</description><language>chi ; eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; TESTING</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090121&DB=EPODOC&CC=CN&NR=100453547C$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,778,883,25547,76298</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090121&DB=EPODOC&CC=CN&NR=100453547C$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GOTO YUKI</creatorcontrib><creatorcontrib>KOBORI AKIO</creatorcontrib><creatorcontrib>NAKATANI KAZUHIKO</creatorcontrib><creatorcontrib>HAGIWARA SHINYA</creatorcontrib><creatorcontrib>HORIE SOUTA</creatorcontrib><creatorcontrib>SAITO ISAO</creatorcontrib><title>Inhibitors</title><description>An inhibitor contains naphthyridine dimer, a naphthyridine-azaquinolone hybrid, a trinaphthyridine-azaquinolone hybrid, or a trinaphthyridine-azaquinolone hybrid derivative. In order to inhibit binding of 100 nM of RRE to 100 nM of Rev protein, for example, an inhibitor containing naphthyridine dimer is used at a molarity of 1.2 muM to 12 muM, an inhibitor containing the naphthyridine-azaquinolone hybrid is used at a molarity of 2 muM to 20 muM, or an inhibitor containing the trinaphthyridine-azaquinolone hybrid derivative is used at a molarity of 200 nM to 2 muM. This makes it possible to effectively inhibit binding of RRE to Rev protein.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>TESTING</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZODyzMvITMosyS8q5mFgTUvMKU7lhdLcDEpuriHOHrqpBfnxqcUFicmpeakl8c5-hgYGJqbGpibmzs7GRCkCAAPvHZI</recordid><startdate>20090121</startdate><enddate>20090121</enddate><creator>GOTO YUKI</creator><creator>KOBORI AKIO</creator><creator>NAKATANI KAZUHIKO</creator><creator>HAGIWARA SHINYA</creator><creator>HORIE SOUTA</creator><creator>SAITO ISAO</creator><scope>EVB</scope></search><sort><creationdate>20090121</creationdate><title>Inhibitors</title><author>GOTO YUKI ; KOBORI AKIO ; NAKATANI KAZUHIKO ; HAGIWARA SHINYA ; HORIE SOUTA ; SAITO ISAO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN100453547CC3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2009</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>TESTING</topic><toplevel>online_resources</toplevel><creatorcontrib>GOTO YUKI</creatorcontrib><creatorcontrib>KOBORI AKIO</creatorcontrib><creatorcontrib>NAKATANI KAZUHIKO</creatorcontrib><creatorcontrib>HAGIWARA SHINYA</creatorcontrib><creatorcontrib>HORIE SOUTA</creatorcontrib><creatorcontrib>SAITO ISAO</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GOTO YUKI</au><au>KOBORI AKIO</au><au>NAKATANI KAZUHIKO</au><au>HAGIWARA SHINYA</au><au>HORIE SOUTA</au><au>SAITO ISAO</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Inhibitors</title><date>2009-01-21</date><risdate>2009</risdate><abstract>An inhibitor contains naphthyridine dimer, a naphthyridine-azaquinolone hybrid, a trinaphthyridine-azaquinolone hybrid, or a trinaphthyridine-azaquinolone hybrid derivative. In order to inhibit binding of 100 nM of RRE to 100 nM of Rev protein, for example, an inhibitor containing naphthyridine dimer is used at a molarity of 1.2 muM to 12 muM, an inhibitor containing the naphthyridine-azaquinolone hybrid is used at a molarity of 2 muM to 20 muM, or an inhibitor containing the trinaphthyridine-azaquinolone hybrid derivative is used at a molarity of 200 nM to 2 muM. This makes it possible to effectively inhibit binding of RRE to Rev protein.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN100453547CC |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TESTING |
| title | Inhibitors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T07%3A40%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GOTO%20YUKI&rft.date=2009-01-21&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN100453547CC%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |